Background: Hepatocellular carcinoma (HCC) is a primary tumor of the liver, which develops in the setting of chronic liver disease. In the Philippines, despite being the third leading site of cancer, there are limited studies on prognostic factors, treatment outcomes and survival.

Objectives: This study aims to investigate prognostic features, treatment outcomes and survival of HCC patients in our institution.

Methodology: Retrospective cohort study was employed. All consecutive patients diagnosed with HCC in our institution from January 2008 to December 2014 were included. Demographic data, tumor characteristics, risk factors and treatment outcomes were retrieved through review of medical records. Cox regression and Kaplan- Meier survival analyses were used to identify prognostic factors and estimate survival, respectively. Statistical analyses were performed with STATA v13.

Results: A total of 346 patients were included. Mean age was 61.47+13.08 years. 55.78% had hepatitis B virus (HBV) infection, 65.15% had cirrhosis solitary nodule (55.08%) was the dominant tumor pattern, mostly involving the right lobe (51.85%) and >3cm (85.48%) in diameter. 43.5% were barcelona clinic liver cancer (BCLC) stage B and 43.81% had advanced stage on presentation (BCLC C/D). Majority did not have portal vein thrombosis (PVT) and distant metastasis. Overall median survival was 13.17 months (range, < one month - 92 months). Those who had locoregional therapy had the longest median survival (30.33 months), followed by systemic chemotherapy (26.67 months) then surgery (13.17 months).

Conclusion: Among HCC patients In our institution, chronic hepatitis B was found to be the primary risk factor for its development. Median survival was 13.17 months with longest median survival among those who received locoregional treatment. Child-Turcotte-Pugh C (CTP C), BCLC stages C and D were independent predictors of mortality.

Keywords: retrospective, hepatocellular carcinoma, survival

1. El-Serag HB, Hepatocellular Carcinoma, NEJM, 2011, 356: 1118- 1127
2. Task Force on Philippine Guidelines on Periodic Health Examination: Philippine Guidelines on Periodic Health Examination (PHEX) Effective Screening for Diseases Among Apparently Healthy Filipinos. The Publications Program, University of the Philippines Manila, 2004
3. Marrero JA, Fontana RJ, Barrat, A, Akari F, Conjeevaram GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort, Hepatology 2005 Apr;41(4):707-16
4. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: Hepatology 1998; 28:751.
5. Davila, JA, Morgan, RO, Shaib, Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study. Gastroenterology 2004; 127:1372.
6. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular Carcinoma in the United states, Prognostic Features, Treatment Outcome and Survival, American Cancer Society, 1996 .
7. El Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, Mcbride R, McGlynn KA. Treatment and outcomes of treating of Hepatocellular Carcinoma among Medicare recipients in the United States: a population based study, Journal of Hepatology, 2005
8. Lucas ZD, Pangan CP, Patal PC, Ong J. The clinical profile of hepatocellular carcinoma patients at the Philippine General Hospital, Philippine Journal of Internal Medicine. 2009;47:1-9
9. Daez ML, Ong JP, Lomboy AR, Libuit JM, Vicente IM, Firmalino GC, Carpio GC. Demographic Profile and Treatment Outcomes of Filipino Patients with Hepatocellular Carcinoma in a Liver Tumor Registry, Acta Medica Philippina. 2012
10. Masao et al. Asia Pacific Association for the Study of the Liver Consensus Recommendations on Hepatocellular Carcinoma. Hepatol lnt (2010)4:439-474.
11. Abdelaziz AO, Elbaz TM, Shousha HI, Ibrahim MM, El Shazli MA, Abdelmaksoud AH, Aziz OA, Zaki HA, Elattar IA, Nabeel MM. Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience, Asian Pacific Journal of Cancer Prevention. 2014; 15:3915-3920
12. Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, Alkis N, Karaglu A, Tarhan O, Unek T, Yilmaz U. Epidemiology and Survival of Hepatocellular Carcinoma in Turkey: Outcome of Multicenter Study. Jpn J Clinical Oncol 2008:38(10)683-688
13. Borzio M, Colloredo G, Pioltelli P, Quagliulo M. Epidemilogy and outcome of hepatocellular carcinoma in Lombardy. Dig Liver Dis 2007;39:1011-1017.
14. Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Marco M, Benvegnu L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F. Italian Liver Cancer group. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015 Jan;61(1):184-190.
15. Bruix et al. American Association for the Study of Liver Diseases Practice Guidelines for Hepatocellular Carcinoma, Hepatology. 2010